ProShare Advisors
KPTI icon

ProShare Advisors’s Karyopharm Therapeutics KPTI Stock Holding History

ProShare Advisors’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,011
Closed -$13.2K – 2097
2024
Q2 		$13.2K Sell
1,011
-346
-25% -$5.73K ﹤0.01% 1826
2024
Q1 		$30.7K Buy
1,357
+107
+9% +$1.88K ﹤0.01% 1955
2023
Q4 		$16.2K Sell
1,250
-229
-15% -$3.09K ﹤0.01% 1928
2023
Q3 		$29.7K Buy
1,479
+5
+0.3% +$112 ﹤0.01% 1762
2023
Q2 		$39.6K Buy
1,474
+339
+30% +$14.6K ﹤0.01% 1791
2023
Q1 		$66.2K Buy
1,135
+20
+2% +$987 ﹤0.01% 1645
2022
Q4 		$56.9K Buy
1,115
+108
+11% +$7.49K ﹤0.01% 1725
2022
Q3 		$83K Buy
1,007
+24
+2% +$1.79K ﹤0.01% 1595
2022
Q2 		$66K Sell
983
-437
-31% -$40.1K ﹤0.01% 1666
2022
Q1 		$158K Sell
1,420
-338
-19% -$42.1K ﹤0.01% 1943
2021
Q4 		$170K Buy
1,758
+68
+4% +$6.78K ﹤0.01% 2086
2021
Q3 		$148K Sell
1,690
-455
-21% -$47.2K ﹤0.01% 1849
2021
Q2 		$332K Buy
2,145
+194
+10% +$28.2K ﹤0.01% 1828
2021
Q1 		$308K Buy
1,951
+158
+9% +$33.3K ﹤0.01% 1789
2020
Q4 		$416K Buy
1,793
+431
+32% +$99.9K ﹤0.01% 1383
2020
Q3 		$298K Sell
1,362
-53
-4% -$13K ﹤0.01% 1182
2020
Q2 		$402K Buy
1,415
+607
+75% +$180K ﹤0.01% 1062
2020
Q1 		$233K Sell
808
-636
-44% -$175K ﹤0.01% 958
2019
Q4 		$415K Sell
1,444
-120
-8% -$26K ﹤0.01% 1162
2019
Q3 		$226K Buy
1,564
+33
+2% +$4.47K ﹤0.01% 1381
2019
Q2 		$138K Sell
1,531
-203
-12% -$16.3K ﹤0.01% 1501
2019
Q1 		$152K Buy
1,734
+22
+1% +$2.44K ﹤0.01% 1522
2018
Q4 		$241K Sell
1,712
-330
-16% -$55.7K ﹤0.01% 1270
2018
Q3 		$522K Sell
2,042
-75
-4% -$20.7K ﹤0.01% 1083
2018
Q2 		$540K Buy
2,117
+288
+16% +$71.2K ﹤0.01% 1076
2018
Q1 		$368K Sell
1,829
-200
-10% -$39.9K ﹤0.01% 1233
2017
Q4 		$292K Buy
2,029
+104
+5% +$16.7K ﹤0.01% 1404
2017
Q3 		$317K Buy
1,925
+115
+6% +$16.5K ﹤0.01% 1119
2017
Q2 		$246K Buy
1,810
+134
+8% +$19.8K ﹤0.01% 1262
2017
Q1 		$323K Sell
1,676
-431
-20% -$69.2K ﹤0.01% 1207
2016
Q4 		$297K Buy
2,107
+438
+26% +$59.2K ﹤0.01% 1373
2016
Q3 		$244K Sell
1,669
-308
-16% -$37K ﹤0.01% 1240
2016
Q2 		$199K Buy
1,977
+25
+1% +$3.25K ﹤0.01% 1429
2016
Q1 		$261K Sell
1,952
-188
-9% -$20.7K ﹤0.01% 1273
2015
Q4 		$425K Buy
2,140
+177
+9% +$38.3K 0.01% 1115
2015
Q3 		$310K Sell
1,963
-133
-6% -$35.6K ﹤0.01% 1132
2015
Q2 		$855K Sell
2,096
-9
-0.4% -$3.89K 0.01% 849
2015
Q1 		$967K Buy
2,105
+467
+29% +$201K 0.01% 860
2014
Q4 		$920K Buy
+1,638
New +$930K 0.01% 898
2014
Q3 		– Sell
-402
Closed -$281K – 2331
2014
Q2 		$281K Sell
402
-126
-24% -$58.6K ﹤0.01% 1952
2014
Q1 		$244K Buy
+528
New +$268K ﹤0.01% 2382

Other funds holding KPTI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

ProShare Advisors's KPTI Position: Q3 2024 in Review

ProShare Advisors sold out of Karyopharm Therapeutics (KPTI) in Q3 2024, closing a stake of 1,011 shares — an estimated $13.2K sold.

ProShare Advisors first reported a position in KPTI in Q1 2014 and held it in 41 quarters. The position peaked at $967K in Q1 2015. 91 funds tracked by Wall St. Rank hold KPTI as of Q3 2024.

  • ProShare Advisors reported no remaining Karyopharm Therapeutics position as of Q3 2024 after selling out during the quarter.
  • ProShare Advisors sold 1,011 Karyopharm Therapeutics shares in Q3 2024, an estimated $13.2K.
  • ProShare Advisors first reported a position in Karyopharm Therapeutics in Q1 2014 and held it in 41 quarters.
  • ProShare Advisors's Karyopharm Therapeutics position peaked at $967K in Q1 2015.
  • 91 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2024.

Based on ProShare Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.